R&D and Innovation


3D229 (Batiraxcept )
Batiraxcept is a high-affinity, soluble Fc-fusion protein designed to bind Growth Arrest Specific 6 (GAS6), intercept the binding of GAS6 to its receptor AXL and block the activation of the GAS6- AXL signaling pathway. We received IND approval for Phase I clinical trial in healthy volunteers in China in May 2021 and completed this Phase I clinical trial in May 2022, and its findings were presented at the CSCO conference in September 2022. In April 2022, we obtained IND approval for a Phase Ib/II clinical trial in patients with NSCLC, RCC and UC. In addition, we obtained IND approval for a on-goning Phase III clinical trial in patients with PROC in China in July 2021 to participate in the MRCT, and we initiated this trial in China in February 2022. As of Decemeber 31, 2022, twelve patients have been enrolled in this MRCT in China.


Function of GAS6/TAM (AXL) pathway

The GAS6-AXL signaling pathway is key to tumor cell growth, cancer metastasis, immune escape and drug tolerance. AXL is reported to be up-regulated in multiple cancer types including acute myeloid leukemia (AML), kidney cancer, pancreatic cancer, breast cancer, lung cancer, ovarian cancer and prostate cancer. Increased expression of AXL and GAS6 in tumors has been correlated with poor prognosis and decreased survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies. Preclinical studies have proved the anti-tumor activity of GAS6-AXL inhibition, either alone or its combination with a variety of antie-cancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs. As a result, GAS6-AXL has attracted wide attention as a new target for cancer treatment.